| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate |
2011-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20120130658-A |
| titleOfInvention |
Peptide fused double target antibody and use thereof |
| abstract |
The present invention is to neutralize VEGFR-2 and c-Met involved in angiogenesis at the same time, to effectively inhibit the signaling mechanisms involved in angiogenesis and cancer cell proliferation, containing a dual target antibody derived from a human monoclonal antibody and the antibody Provided are compositions for inhibiting angiogenesis and treating cancer. The dual target antibody according to the present invention simultaneously neutralizes two targets involved in angiogenesis and cancer cell proliferation, thereby exhibiting superior neutralizing ability as compared to the conventional single target antibody, and is very effective in treating cancer. In addition, for the two targets that are correlated with each other, by producing a double-target antibody of the present invention can be expected to be superior to the benefit of the single-target antibody treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9637541-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155627-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017200173-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10246507-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160044774-A |
| priorityDate |
2011-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |